Similar Survival in Patients Following Heart Transplantation Receiving Induction Therapy Using Daclizumab vs. Basiliximab

BACKGROUND: Induction therapy with interleukin-2 receptor antagonists has been established as an effective immunosuppressive strategy in the management of heart transplant (HTx) recipients. We compared outcomes following HTx in patients receiving basiliximab, daclizumab, or no induction therapy. MET...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Circ J
Главные авторы: Martin, Spencer T., Kato, Tomoko S., Farr, Maryjane, McKeen, Jaclyn T., Cheema, Faisal, Ji, Mengxi, Ross, Alexandra, Yerebakan, Halit, Naka, Yoshifumi, Takayama, Hiroo, Restaino, Susan, Mancini, Donna, Schulze, P. Christian
Формат: Artigo
Язык:Inglês
Опубликовано: 2014
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4967552/
https://ncbi.nlm.nih.gov/pubmed/25501951
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circj.CJ-14-0718
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы